Skip to content

Are You a Healthcare Professional?

This European website, initiated and developed by CSL Behring, has two separate sections with the aim to provide information on haemophilia for an international audience, either to European healthcare professionals or to the general public.*

Yes, I am a healthcare professional*

No, I am not a healthcare professional

*CSL Behring is legally obliged to restrict some areas of the website to healthcare professionals only. By clicking “Yes, I am a Healthcare Professional”, you confirm this statement is true and you accept all liability related to the above. If you are not a healthcare professional you can visit the section of this website for the general public.


  1. Srivastava A, Santagostino E, Dougall A, et al. WFH guideline for the management of hemophilia, 3rd edition. Haemophilia. 2020;00:1-158.
  2. Nathwani AC, Reiss UM, Tuddenham EGD, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371:1994-2004.
  3. Rangarajan S, Walsh L, Lester W, et al. AAV5-Factor VIII gene transfer in severe hemophilia A. N Engl J Med. 2017;377(26):2519-2530.
  4. Berntorp E, Fischer K, Hart DP, et al. Haemophilia. Nat Rev Dis Primers. 2021;7:45.
  5. National Organization for Rare Disorders (NORD). Rare Disease Database-Hemophilia B. Accessed October 27, 2021.
  6. National Organization for Rare Disorders (NORD). Rare Disease Database-Hemophilia A. Accessed October 27, 2021.
  7. Mehta P, Reddivari AKR. Hemophilia. [Updated 2023 Jun 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from:
  8. Mancuso ME, Santagostino E. Outcome of clinical trials with new extended half-life FVIII/IX concentrates. J Clin Med. 2017;6,39.
  9. High KA, Roncarolo MG. Gene therapy. N Engl J Med. 2019;381(5):455-464.
  10. McCain J. The future of gene therapy. Biotechnol Healthc. 2005;2(3):52-54,56-60.
  11. Morfini M. The history of clotting factor concentrates pharmacokinetics. J Clin Med. 2017;6,35.
  12. European Medicines Agency (EMA). BeneFIX. Accessed November 30, 2021.
  13. European Medicines Agency (EMA). ReFacto AF. Accessed November 30, 2021.
  14. Hemophilia Federation of America (HFA). Bleeding Disorders Historical Timeline. Accessed July 14, 2023.
  15. White GC. Hemophilia: an amazing 35-year journey from the depths of HIV to the threshold of cure. Trans Am Clin Climatol Assoc. 2010;121:61-73; discussion 74-5. PMID: 20697550; PMCID: PMC2917149.
  16. Nathwani AC, Tuddenham EGD, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357-2365.
  17. Heinz S, Braspenning J. Measurement of blood coagulation factor synthesis in cultures of human hepatocytes. Methods Mol Biol. 2015;1250:309-16.
  18. Ay C, Feistritzer C, Rettl J, et al. Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria. Sci Rep. 2021;11(1):12967.
  19. Chhabra A, Spurden D, Fogarty PF, et al. Real-world outcomes associated with standard half-life and extended half-life factor replacement products for treatment of haemophilia A and B. Blood Coagul Fibrinolysis. 2020;31(3):186-192.
  20. Perrin GQ, Herzog RW, Markusic DM. Update on clinical gene therapy for hemophilia. Blood. 2019;133(5):407-414.
  21. Pool JG, Hershgold EJ, Pappenhagen AR. High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. Nature. 1964;203:312.
  22. Kasper CK, Kipnis SA. Hepatitis and clotting-factor concentrates. JAMA 1972;221(5):510.
  23. European Medicines Agency (EMA). Elocta. Accessed October 30, 2021.
  24. European Medicines Agency (EMA). Alprolix. Accessed October 30, 2021.
  25. European Medicines Agency (EMA). Roctavian. Accessed January 28, 2023.
  26. Food and Drug Administration. Approved Cellular and Gene Therapy Products. Accessed September 5, 2023.
  27. European Medicines Agency (EMA). Hemgenix. Accessed January 28, 2023.